- Home
- DNTH vs LBTYA Comparison
DNTH vs LBTYA Comparison
Compare DNTH & LBTYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNTH | LBTYA |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Bermuda |
| Employees | N/A | 6636 |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.0B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | DNTH | LBTYA |
|---|---|---|
| Price | $95.71 | $10.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 5 |
| Target Price | ★ $121.00 | $13.72 |
| AVG Volume (30 Days) | 1.2M | ★ 2.2M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,036,000.00 | N/A |
| Revenue This Year | N/A | $15.41 |
| Revenue Next Year | $29.48 | $3.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.08 | $9.62 |
| 52 Week High | $102.33 | $13.52 |
Technical Indicators
Market Signals| Indicator | DNTH | LBTYA |
|---|---|---|
| Relative Strength Index (RSI) | 58.43 | 32.79 |
| Support Level | $79.27 | $10.38 |
| Resistance Level | $98.70 | $11.56 |
| Average True Range (ATR) | 5.37 | 0.34 |
| MACD | 0.83 | -0.07 |
| Stochastic Oscillator | 68.41 | 10.00 |
Price Performance
Historical ComparisonAbout DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
About LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.